

| | |
|-------------------------|-------------------|
| Reference: | FOI.16802.25 |
| Subject: | Urothelial cancer |
| Date of Request: | 10 March 2025 |

Requested:

1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment

2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
 - Atezolizumab (Tecentriq)
 - Avelumab (Bavencio)
 - Carboplatin single agent or in any other combination
 - Carboplatin with Gemcitabine
 - Carboplatin with Gemcitabine + Avelumab (Bavencio)
 - Carboplatin with Paclitaxel
 - Cisplatin single agent or in any other combination
 - Cisplatin with Gemcitabine
 - Cisplatin with Gemcitabine + Nivolumab (Opdivo)
 - Cisplatin with Gemcitabine + Avelumab (Bavencio)
 - Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
 - Nivolumab (Opdivo)
 - Pembrolizumab (Keytruda)
 - Other active systemic anti-cancer therapy
 - Palliative care only
 - Erdafitinib

3. How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies:
 - Carboplatin single agent or in any other combination
 - Carboplatin with Gemcitabine
 - Carboplatin with Gemcitabine + Avelumab (Bavencio)
 - Carboplatin with Paclitaxel
 - Cisplatin single agent or in any other combination
 - Cisplatin with Gemcitabine
 - Cisplatin with Gemcitabine + Avelumab (Bavencio)

4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested for question 2, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated

cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested for palliative care, the UHB would need to undertake a manual trawl of the medical records of patients that are receiving palliative care and those receiving treatment for Urothelial cancer, to identify any information that would fulfil these parts of your request, as this is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds below.

Additionally, where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB confirms that it does treat patients for Urothelial cancer.
2. The UHB provides, within the table overleaf, the number of patients that were treated for Urothelial cancer, at any stage, with the listed medications, during the period 1 December 2024 to 28 February 2025.

| Treatment | Number |
|--|---------------|
| Atezolizumab (Tecentriq) | 6 |
| Avelumab (Bavencio) | * |
| Carboplatin single agent or in any other combination | 0 |
| Carboplatin with Gemcitabine | * |
| Carboplatin with Gemcitabine + Avelumab (Bavencio) | 0 |
| Carboplatin with Paclitaxel | 0 |
| Cisplatin single agent or in any other combination | 0 |
| Cisplatin with Gemcitabine | * |
| Cisplatin with Gemcitabine + Nivolumab (Opdivo) | 0 |
| Cisplatin with Gemcitabine + Avelumab (Bavencio) | 0 |

| | |
|--|------------------------------|
| Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) | 0 |
| Nivolumab (Opdivo) | 0 |
| Pembrolizumab (Keytruda) | 0 |
| Other active systemic anti-cancer therapy | * |
| Palliative care only | Section 12 exemption applied |
| Erdafitinib | 0 |

3. The UHB provides, within the table overleaf, the number of patients that have been treated for metastatic Urothelial cancer with the listed medications, during the period 1 December 2024 to 28 February 2025.

| Treatment | Number |
|--|--------|
| Carboplatin single agent or in any other combination | 0 |
| Carboplatin with Gemcitabine | * |
| Carboplatin with Gemcitabine + Avelumab (Bavencio) | 0 |
| Carboplatin with Paclitaxel | 0 |
| Cisplatin single agent or in any other combination | 0 |
| Cisplatin with Gemcitabine | 0 |
| Cisplatin with Gemcitabine + Avelumab (Bavencio) | 0 |

4. The UHB is not currently participating in any clinical trials for Urothelial cancer.